Ofatumumab was tested in a pivotal study in 154 patients with CLL, a type of B cell tumour. Among the 59 participants who were refractory to fludarabine and alemtuzumab, 58% responded to ofatumumab treatment. Response rates were comparable between those who had previously received rituximab and those who had not.
Arzerra has been conditionally approved by the European Medicines Agency; therefore, the agency will review any new data on the product annually.
Further information: GlaxoSmithKline